Amgen Inc.

Other

Synergen, Inc.

Angen Inc.

Tadahiko Kohno

Robert C Thompson

Jack Lile

Michael T Brewer

Mary S Rosendahl

Rebecca W Vanderslice

Susan Bektesh

Charles C Squires

Duane Bonam

Michael W King

Karin K Hale

Frank Collins

Susan Becktesh

Frank D Collins

James Vannice

Drizislav Mismer, Deceased

Apo-AI/AII peptide derivatives

Compounds are disclosed having the general formula R -X-R , wherein R and R are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R and R may be the same or different. Preferred R and R groups are TNF inhibitors.

PEGylation reagents and compounds formed therewith

The present invention provides nucleic acid molecules encoding a 30kDa TNF inhibitor or a fragment thereof having at least one non-native cysteine residue at the N-terminus, C-terminus, residue 14, or residue 15.

Nucleic acids encoding TNF inhibitor and method of production

At least two substantially purified tumor necrosis factor (TNF) inhibitors are disclosed which are glycoproteins that are active against TNF. The isolation of 3O kDa and 40 KDa TNF inhibitor from urine is disclosed. The deglycosylated form of the 3O kDa TNF inhibitor and 40 kDa TNF inhibitor are described as being active against TNF. The 40 kDa TNF inhibitor is active against both TNF alpha a TNF beta. The amino acid sequence of the 30 kDa TNF inhibitor and the 40 kDa TNF inhibitor are disclosed. Methods for isolating the TNF inhibitors from human U937 cell medium and producing the proteins by recombinant-DNA methods are also described.

Tumor necrosis factor (TNF) inhibitor and method for obtaining the same

This invention describes processes for producing mature human members of the NGF/BDNF family of neurotrophic proteins that are fully biologically active. In addition, the gene encoding human BDNF and human BDNF are disclosed. A previously-unreported member of the NGF/BDNF family of neurotrophic proteins, NGF-3, has been identified and a portion of the gene encoding for the NGF-3 has been described.

Production of biologically active NGF proteins

A process for the production of biologically active recombinant neurotrophic factor from the NGF/BDNF family is described. The process is comprised of a) constructing a synthetic neurotrophic factor gene suitable for expression in a bacterial expression system; b) the synthetic neurotrophic factor gene is expressed in a bacterial expression system; c) the neurotrophic factor is solubilized and sulfonylated; d) sulfonylated neurotrophic factor is allowed to refold in the presence of polyethylene glycol and urea; and e) biologically active neurotrophic factor is isolated and purified.

Production and purification of biologically active recombinant

This invention describes processes for producing mature human members of the NGF/BDNF family of neurotrophic proteins that are fully biologically active. In addition, the gene encoding human BDNF and processes for obtaining the same are disclosed. A previously-unreported member of the NGF/BDNF family of neurotrophic proteins, NGF-3, has been identified and a portion of the gene encoding for the NGF-3 has been described. Processes for identifying additional previously unreported members of the NGF/BDNF family are also described.

Production of biologically active, recombinant members of the NGF/BDNF

Growing community of inventors

Thousand Oaks, CA, United States of America

Tadahiko Kohno